What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “This Phase 2 study evaluates TL938 alone or in combination with trastuzumab in patients with HER2-positive advanced colorectal cancer. Cohort 1 determines the recommended Phase 2 dose of TL938 with trastuzumab. Cohorts 2 and 3 evaluate the efficacy and safety of TL938 with trastuzumab or TL938 alone at that dose.”In the company’s words, NCT06589830 on ClinicalTrials.gov
Other drugs for Colorectal Cancer Metastatic
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up1
- Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovCompletion date moved: 2026-10 to 2028-12 · ClinicalTrials.gov NCT06589830
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2028 | TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026